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Juvenile parkinsonism is a rare movement disorder. In pedi-
atric patients, the manifestations are more complex and
varied, which makes the diagnosis challenging. It may occa-
sionally manifest as another disease such as dopa-responsive
dystonia, Wilson disease, or neurodegeneration with brain
iron accumulation (i.e., HallervordeneSpatz disease).1,2
This paper reports a 14-year-old girl who experienced a va-
riety of movement disorders such as parkinsonism and dys-
tonia. Her symptoms changed and worsened within a few
years, but dramatically improved with levodopa treatment.
2. Case Report
A 14-year-old girl was first brought to the outpatient clinic
because of progressively slowing gait, tremors, and limbs
dystonia. During infancy, she was relatively quiet and less
energetic in comparison to other babies. She started
walking at the age of 1 year and 8 months, but only started
talking at 3 years old. Her parents observed the develop-
mental delay, but did not have her undergo further* Corresponding author. Division of Pediatric Neurology, Depart-
ment of Pediatrics, Chung Shan Medical University Hospital, Num-
ber 110, Section 1, Jianguo North Road, South District, Taichung
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tremors, upper extremity dystonia, and dysarthria.
By the time she was 13 years old, her symptoms had
worsened and repetitive stereotyped behaviors began.
Soon after, she began to experience fecal and urine in-
continence, and she lacked facial expression, drooled un-
controllably, and screamed loudly and meaninglessly. She
was administered various medicines such as anticholinergic
drugs, dopamine antagonists, and antipsychotics, but these
all failed to stop the deterioration of her symptoms. When
she presented to the outpatient service at the age of 14
years, she could neither walk nor stand.
Neurologic and physical examinations revealed marked
generalized spasticity and extreme postural instability. Her
range of eye motion was full, but she had facial masking,
hand dystonia, increased deep tendon reflexes, and knee
jerks. Muscle power in all extremities was full and sensation
was intact. Routine blood tests such as complete blood
count, differential count, copper, ceruloplasmin, iron,
ferritin, lactate, amino acids, organic acids, and thyroid
function were within normal limits. Chromosome analysis
and tests for the methyl CpG binding protein 2 (MECP2) gene
and pantothenate kinase 2 (PANK2) gene were also normal.
Electroencephalography showed no epileptiform dis-
charges but showed a slow background. Brain magnetic
resonance imaging obtained at 13 years of age demon-
strated bilateral symmetric low-intensity signals in the T2
images of the globus pallidus. Proton magnetic resonance
spectroscopy (MRS) revealed a decreased N-acetylaspartatey Elsevier Taiwan LLC. All rights reserved.
Figure 1 Brain magnetic resonance T2 image of the patient
at 13 years old reveals bilateral symmetric low-intensity signal
in the globus pallidus (left, arrow). The proton magnetic
resonance spectroscopy image reveals an abnormally
decreased n-acetylaspartate peak in the basal ganglia (upper
right, arrow) in contrast to the normal n-acetylaspartate peak
(lower right) in the contralateral gray matter area.
154 S.-Y. Hong, I.-C. Leepeak in the basal ganglia at 14 years of age (Figure 1). The
Tc99m-ECD brain perfusion single-photon emission
computed tomography (SPECT), also obtained at 14 years of
age, revealed hypoperfusion of the left basal ganglia.
Her parents do not remember any history of movement
or neurodegenerative disorders. Tracing her previous
medical record showed she received dopamine antagonists
and antipsychotics, which worsened her clinical condition.
This time, she was administered levodopa at 1 mg/kg/
day that was gradually increased to twice daily. Soon after,
her slow gait and dystonia dramatically improved. Her
tremors were also successfully controlled. Within 1 week
after starting levodopa treatment, she was able to walk and
her hand tremors and dystonia improved significantly.
3. Discussion
Parkinsonism is common in adults; it typically manifests in
middle and late life. However, a juvenile form can occur
before the age of 20 years.3 In pediatric patients, juvenile
parkinsonism is often difficult to diagnose and manage. The
variable symptoms and etiologies make it difficult to iden-
tify juvenile parkinsonism; because of the possible adverse
effects of levodopa, many clinicians hesitate to use it in the
early stage of the disease.4
In this patient, parkinsonism combined with dystonia is a
more accurate description of her symptoms. However, some
monamine neurotransmitter metabolism disorders (e.g.,
dopa-responsive dystonia, sepiapterin reductase deficiency)
may present with similar features. Based on her SPECT
scanning (e.g., hypoperfusion of the left basal ganglia) and
neuroimaging findings (e.g., basal ganglia T2 hypointensity),
the most likely etiology was neurodegeneration with ironaccumulation in the brain.5 In recent years, similar disorders
of brain iron content without PANK2 mutations such as
aceruloplasminemia, neuroferritinopathy, and infantile
neuroaxonal dystrophy have been classified as disorders of
neurodegeneration with brain iron accumulation.6 However,
because of the availability of genetic testing and because
PANK2 accounts for nearly one-half of cases, PANK2 was
chosen for genetic testing. The results showed she had no
mutation in the gene.
Levodopa is the most effective drug in the treatment of
parkinsonism7; however, its effectiveness in pediatric pa-
tients remains unclear. This report underscores how the
early and decisive use of levodopa can effectively improve
juvenile parkinsonism with unknown cause, perhaps even as
a diagnosis of exclusion by treatment.Conflicts of interest
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